1.14897

Chloride Test, photometric

photometric, 2.5-250 mg/L (Cl^-), Spectroquant^®

• UNSPSCコード: 41116116
• NACRES: NA.24

特性

• product name: Chloride Test, photometric, 2.5-250 mg/L (Cl^-), Spectroquant^®
• 製品種目: Spectroquant^®
• 品質水準: 100
• 使用法: sufficient for 100 tests; sufficient for 175 tests (depending on package size)
• 特定アナライト: chloride
• 測定範囲: 2.5-250 mg/L (Cl^-)
• テクニック: photometry: suitable
• 適合性: for use with Spectroquant^® Move 100; for use with Spectroquant^® Nova 60 A; for use with Spectroquant^® Prove 100; for use with Spectroquant^® Prove 300; for use with Spectroquant^® Prove 600
• 検出方法: photometric (Iron(III)-thiocyanate)
• 保管温度: 15-25°C

詳細

詳細

Method: photometric 2.5 - 250 mg/l Cl⁻ Spectroquant^®
This Spectroquant^® Chloride test allows the accurate quantification of chloride ions in various waters and waste water. Their concentration depends on geological factors and the general local situation. Within the test chloride ions react with mercury(II)-thiocyanate to mercury(II) chloride. The liberated thiocyanide reacts with iron ions to form a read complex. The method is analogous to EPA 325.1 and APHA 4500-Cl- E.
All our Cell and Reagent Test Kits are equipped with the unique Live ID (2D barcode) which allows seamless method recognition and contains essential information such as lot number, expiry date, and automatic calibration updates.
The Spectroquant^® Reagent Test Kits contain highly stable, ready-to-use reagent mixtures to perform the analysis according to the procedure described in the accompanying instruction leaflet.

アプリケーション

• PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.: This study demonstrates the use of PREFUL MRI to monitor changes in perfusion and ventilation in cystic fibrosis patients post-therapy, showcasing its potential for non-invasive assessment in clinical settings (Dohna et al., 2024).
• Wearable sweat chloride sensors: materials, fabrication and their applications.: Reviews advances in materials and fabrication techniques for wearable sweat chloride sensors, discussing their significant potential for real-time health monitoring and diagnostics (Patel et al., 2024).
• Initial characteristics of cystic fibrosis in Algeria: Description of 34 pediatric cases.: Provides an overview of the clinical presentation and initial characteristics of cystic fibrosis in a pediatric Algerian cohort, contributing to the regional understanding of this genetic disorder (Bendoukha et al., 2024).

法的情報

SPECTROQUANT is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• ピクトグラム: GHS05,GHS06,GHS08,GHS09
• シグナルワード: Danger
• 危険有害性情報: H290 - H302 + H332 - H311 - H314 - H373 - H410
• 注意書き: P273 - P280 - P303 + P361 + P353 - P304 + P340 + P310 - P305 + P351 + P338 - P314
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Met. Corr. 1 - Skin Corr. 1B - STOT RE 2
• 保管分類コード: 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 3
• 引火点(°F): 188.6 °F
• 引火点(℃): 87 °C